Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study - PubMed
6 hours ago
- #Disease-Modifying Therapy
- #Multiple Sclerosis
- #Cohort Study
- High-risk patients for aggressive MS are defined as aged ≥35 at symptom onset with EDSS ≥3 within first year.
- Low-risk patients are those without these features.
- High-efficacy disease-modifying therapy (HE-DMT) reduces relapse risk in both high-risk and low-risk groups.
- No evidence found for differential treatment benefit based on MS severity.
- Overall, no significant difference in disability outcomes between HE-DMT-treated and untreated periods observed.
- Among patients ever exposed to HE-DMT, treatment reduced risk of disability worsening.
- Lowest relapse risk seen in low-risk group treated with HE-DMT.
- HE-DMT associated with relapse risk comparable to low-risk untreated group.
- Secondary analysis restricted to HE-DMT recipients showed disability worsening reduced in high-risk group.
- Study uses data from MSBase and OFSEP registries, including 10,405 individuals.